Some molecular targets for antihyperlipidemic drug research

• Hyperlipidaemia is the underlying factor for CVD and stroke.
• Problems still associated with currently available drugs in the therapy.
• Antihyperlipidemic drug discovery research is an area of great interest.
• New molecular targets for NDDR can give novel leads.
• Such 20 different targets discussed in details.

High levels of cholesterol and other lipid constituents are major risk factors in the development of atherosclerosis as well as diseases and disorders associated with it. Though, drugs of various categories acting through different mechanisms are available for antihyperlipidemic therapy, there are limitations associated with each of them, keeping the interest in discovery of newer and better antihyperlipidemic drugs alive. Identification and exploitation of novel molecular targets for discovery of new antihyperlipidemic drugs is an important area of research. Twenty such drug targets are elaborated herein, for their biochemical roles, structures, estimations, as well as, exploitation for new drug discovery research. Few recently discovered drugs are based on such molecular targets are also discussed.

A review on the roles of twenty molecular targets in hyperlipidaemia and atherosclerosis leading to CVD, their mechanism of action in biochemical-biosynthetic lipid pathways and literature reports on their recent studies. Figure optionsDownload as PowerPoint slide